换肤

赛伦生物

i问董秘

A03457

主营介绍

  • 主营业务：

    研究、开发、生产及销售针对生物毒素及生物安全领域的预防和治疗药物。

  • 产品类型：

    抗毒素、抗血清

  • 产品名称：

    抗蛇毒血清 、 马破免疫球蛋白 、 抗狂犬病血清

  • 经营范围：

    从事生物技术专业领域内的技术开发、技术转让、技术咨询、技术服务，血清抗毒素生产，从事货物及技术的进出口业务，医疗器械销售，实业投资，投资管理。【依法须经批准的项目，经相关部门批准后方可开展经营活动】

主营构成分析

报告期
报告期
{"2021-06-30":{"YYSR":{"2":[["\u6297\u86c7\u6bd2\u8840\u6e05","5906.45"],["\u9a6c\u7834\u514d\u75ab\u7403\u86cb\u767d","3576.06"],["\u5176\u4ed6\u4e1a\u52a1\u6536\u5165","109.43"],["\u6297\u72c2\u72ac\u75c5\u8840\u6e05","0.02"]],"3":[["\u534e\u4e1c\u534e\u4e2d\u5730\u533a","6647.17"],["\u534e\u5357\u897f\u5357\u5730\u533a","2745.88"],["\u5176\u4ed6\u4e1a\u52a1\u6536\u5165","109.43"],["\u4e1c\u5317\u534e\u5317\u5730\u533a","81.75"],["\u5176\u4ed6","7.73"]]},"YYCB":{"2":[["\u6297\u86c7\u6bd2\u8840\u6e05","559.72"],["\u9a6c\u7834\u514d\u75ab\u7403\u86cb\u767d","961.38"],["\u5176\u4ed6\u4e1a\u52a1\u6536\u5165",""],["\u6297\u72c2\u72ac\u75c5\u8840\u6e05","0.03"]],"3":[["\u534e\u4e1c\u534e\u4e2d\u5730\u533a",""],["\u534e\u5357\u897f\u5357\u5730\u533a",""],["\u5176\u4ed6\u4e1a\u52a1\u6536\u5165",""],["\u4e1c\u5317\u534e\u5317\u5730\u533a",""],["\u5176\u4ed6",""]]},"LRBL":{"2":[["\u6297\u86c7\u6bd2\u8840\u6e05","67.16"],["\u9a6c\u7834\u514d\u75ab\u7403\u86cb\u767d","32.84"],["\u5176\u4ed6\u4e1a\u52a1\u6536\u5165",""],["\u6297\u72c2\u72ac\u75c5\u8840\u6e05","-0.0001"]],"3":[["\u534e\u4e1c\u534e\u4e2d\u5730\u533a",""],["\u534e\u5357\u897f\u5357\u5730\u533a",""],["\u5176\u4ed6\u4e1a\u52a1\u6536\u5165",""],["\u4e1c\u5317\u534e\u5317\u5730\u533a",""],["\u5176\u4ed6",""]]}},"2020-12-31":{"YYSR":{"2":[["\u6297\u86c7\u6bd2\u8840\u6e05","11276.72"],["\u9a6c\u7834\u514d\u75ab\u7403\u86cb\u767d","7267.10"],["\u5176\u4ed6\u4e1a\u52a1\u6536\u5165","11.36"],["\u6297\u72c2\u72ac\u75c5\u8840\u6e05","1.11"]],"3":[["\u534e\u4e1c\u534e\u4e2d\u5730\u533a","12542.31"],["\u534e\u5357\u897f\u5357\u5730\u533a","5420.62"],["\u4e1c\u5317\u534e\u5317\u5730\u533a","440.83"],["\u5176\u4ed6","141.16"],["\u5176\u4ed6\u4e1a\u52a1\u6536\u5165","11.36"]]},"YYCB":{"2":[["\u6297\u86c7\u6bd2\u8840\u6e05","1164.21"],["\u9a6c\u7834\u514d\u75ab\u7403\u86cb\u767d","1786.76"],["\u5176\u4ed6\u4e1a\u52a1\u6536\u5165","1.83"],["\u6297\u72c2\u72ac\u75c5\u8840\u6e05","2.00"]],"3":[["\u534e\u4e1c\u534e\u4e2d\u5730\u533a",""],["\u534e\u5357\u897f\u5357\u5730\u533a",""],["\u4e1c\u5317\u534e\u5317\u5730\u533a",""],["\u5176\u4ed6",""],["\u5176\u4ed6\u4e1a\u52a1\u6536\u5165","1.83"]]},"LRBL":{"2":[["\u6297\u86c7\u6bd2\u8840\u6e05","64.82"],["\u9a6c\u7834\u514d\u75ab\u7403\u86cb\u767d","35.13"],["\u5176\u4ed6\u4e1a\u52a1\u6536\u5165","0.06"],["\u6297\u72c2\u72ac\u75c5\u8840\u6e05","-0.0057"]],"3":[["\u534e\u4e1c\u534e\u4e2d\u5730\u533a",""],["\u534e\u5357\u897f\u5357\u5730\u533a",""],["\u4e1c\u5317\u534e\u5317\u5730\u533a",""],["\u5176\u4ed6",""],["\u5176\u4ed6\u4e1a\u52a1\u6536\u5165","100.00"]]}},"2020-06-30":{"YYSR":{"2":[["\u6297\u86c7\u6bd2\u8840\u6e05","4575.32"],["\u9a6c\u7834\u514d\u75ab\u7403\u86cb\u767d","2979.63"],["\u5176\u4ed6\u4e1a\u52a1","3.88"],["\u6297\u72c2\u72ac\u75c5\u8840\u6e05","1.11"]],"3":[["\u534e\u4e1c\u534e\u4e2d\u5730\u533a","5350.97"],["\u534e\u5357\u897f\u5357\u5730\u533a","1841.77"],["\u4e1c\u5317\u534e\u5317\u5730\u533a","241.45"],["\u5176\u4ed6","121.87"]]},"YYCB":{"2":[["\u6297\u86c7\u6bd2\u8840\u6e05","406.84"],["\u9a6c\u7834\u514d\u75ab\u7403\u86cb\u767d","712.39"],["\u5176\u4ed6\u4e1a\u52a1","1.83"],["\u6297\u72c2\u72ac\u75c5\u8840\u6e05","2.00"]],"3":[["\u534e\u4e1c\u534e\u4e2d\u5730\u533a",""],["\u534e\u5357\u897f\u5357\u5730\u533a",""],["\u4e1c\u5317\u534e\u5317\u5730\u533a",""],["\u5176\u4ed6",""]]},"LRBL":{"2":[["\u6297\u86c7\u6bd2\u8840\u6e05","64.76"],["\u9a6c\u7834\u514d\u75ab\u7403\u86cb\u767d","35.22"],["\u5176\u4ed6\u4e1a\u52a1","0.03"],["\u6297\u72c2\u72ac\u75c5\u8840\u6e05","-0.01"]],"3":[["\u534e\u4e1c\u534e\u4e2d\u5730\u533a",""],["\u534e\u5357\u897f\u5357\u5730\u533a",""],["\u4e1c\u5317\u534e\u5317\u5730\u533a",""],["\u5176\u4ed6",""]]}}}
{"YYSR":{"chartWrap2":[{"name":"\u6297\u86c7\u6bd2\u8840\u6e05","timeData":["2021-06-30","2020-12-31","2020-06-30"],"lineData":[5906.45,11276.72,4575.32],"columnData":[61.58,60.77,60.52],"unit":["5906.45\u4e07","1.13\u4ebf","4575.32\u4e07"]},{"name":"\u9a6c\u7834\u514d\u75ab\u7403\u86cb\u767d","timeData":["2021-06-30","2020-12-31","2020-06-30"],"lineData":[3576.06,7267.1,2979.63],"columnData":[37.28,39.16,39.41],"unit":["3576.06\u4e07","7267.10\u4e07","2979.63\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u6536\u5165","timeData":["2021-06-30","2020-12-31"],"lineData":[109.43,11.36],"columnData":[1.14,0.06],"unit":["109.43\u4e07","11.36\u4e07"]},{"name":"\u6297\u72c2\u72ac\u75c5\u8840\u6e05","timeData":["2021-06-30","2020-12-31","2020-06-30"],"lineData":[0.02,1.11,1.11],"columnData":[0.0002,0.006,0.01],"unit":["200.00","1.11\u4e07","1.11\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1","timeData":["2020-06-30"],"lineData":[3.88],"columnData":[0.05],"unit":["3.88\u4e07"]}],"chartWrap3":[{"name":"\u534e\u4e1c\u534e\u4e2d\u5730\u533a","timeData":["2021-06-30","2020-12-31","2020-06-30"],"lineData":[6647.17,12542.31,5350.97],"columnData":[69.3,67.59,70.82],"unit":["6647.17\u4e07","1.25\u4ebf","5350.97\u4e07"]},{"name":"\u534e\u5357\u897f\u5357\u5730\u533a","timeData":["2021-06-30","2020-12-31","2020-06-30"],"lineData":[2745.88,5420.62,1841.77],"columnData":[28.63,29.21,24.37],"unit":["2745.88\u4e07","5420.62\u4e07","1841.77\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u6536\u5165","timeData":["2021-06-30","2020-12-31"],"lineData":[109.43,11.36],"columnData":[1.14,0.06],"unit":["109.43\u4e07","11.36\u4e07"]},{"name":"\u4e1c\u5317\u534e\u5317\u5730\u533a","timeData":["2021-06-30","2020-12-31","2020-06-30"],"lineData":[81.75,440.83,241.45],"columnData":[0.85,2.38,3.2],"unit":["81.75\u4e07","440.83\u4e07","241.45\u4e07"]},{"name":"\u5176\u4ed6","timeData":["2021-06-30","2020-12-31","2020-06-30"],"lineData":[7.73,141.16,121.87],"columnData":[0.08,0.76,1.61],"unit":["7.73\u4e07","141.16\u4e07","121.87\u4e07"]}]},"YYCB":{"chartWrap2":[{"name":"\u6297\u86c7\u6bd2\u8840\u6e05","timeData":["2021-06-30","2020-12-31","2020-06-30"],"lineData":[559.72,1164.21,406.84],"columnData":[36.8,39.4,36.23],"unit":["559.72\u4e07","1164.21\u4e07","406.84\u4e07"]},{"name":"\u9a6c\u7834\u514d\u75ab\u7403\u86cb\u767d","timeData":["2021-06-30","2020-12-31","2020-06-30"],"lineData":[961.38,1786.76,712.39],"columnData":[63.2,60.47,63.43],"unit":["961.38\u4e07","1786.76\u4e07","712.39\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u6536\u5165","timeData":["2021-06-30","2020-12-31"],"lineData":[0,1.83],"columnData":[0,0.06],"unit":["0.00","1.83\u4e07"]},{"name":"\u6297\u72c2\u72ac\u75c5\u8840\u6e05","timeData":["2021-06-30","2020-12-31","2020-06-30"],"lineData":[0.03,2,2],"columnData":[0.002,0.07,0.18],"unit":["300.00","2.00\u4e07","2.00\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1","timeData":["2020-06-30"],"lineData":[1.83],"columnData":[0.16],"unit":["1.83\u4e07"]}],"chartWrap3":[{"name":"\u534e\u4e1c\u534e\u4e2d\u5730\u533a","timeData":["2021-06-30","2020-12-31","2020-06-30"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u534e\u5357\u897f\u5357\u5730\u533a","timeData":["2021-06-30","2020-12-31","2020-06-30"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u6536\u5165","timeData":["2021-06-30","2020-12-31"],"lineData":[0,1.83],"columnData":[0,100],"unit":["0.00","1.83\u4e07"]},{"name":"\u4e1c\u5317\u534e\u5317\u5730\u533a","timeData":["2021-06-30","2020-12-31","2020-06-30"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u5176\u4ed6","timeData":["2021-06-30","2020-12-31","2020-06-30"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]}]},"LRBL":{"chartWrap2":[{"name":"\u6297\u86c7\u6bd2\u8840\u6e05","timeData":["2021-06-30","2020-12-31","2020-06-30"],"lineData":[67.16,64.82,64.76],"columnData":[67.16,64.82,64.76],"unit":["67.16\u4e07","64.82\u4e07","64.76\u4e07"]},{"name":"\u9a6c\u7834\u514d\u75ab\u7403\u86cb\u767d","timeData":["2021-06-30","2020-12-31","2020-06-30"],"lineData":[32.84,35.13,35.22],"columnData":[32.84,35.13,35.22],"unit":["32.84\u4e07","35.13\u4e07","35.22\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u6536\u5165","timeData":["2021-06-30","2020-12-31"],"lineData":[0,0.06],"columnData":[0,0.06],"unit":["0.00","600.00"]},{"name":"\u6297\u72c2\u72ac\u75c5\u8840\u6e05","timeData":["2021-06-30","2020-12-31","2020-06-30"],"lineData":[-0.0001,-0.0057,-0.01],"columnData":[-0.0001,-0.0057,-0.01],"unit":["-1","-57","-100"]},{"name":"\u5176\u4ed6\u4e1a\u52a1","timeData":["2020-06-30"],"lineData":[0.03],"columnData":[0.03],"unit":["300.00"]}],"chartWrap3":[{"name":"\u534e\u4e1c\u534e\u4e2d\u5730\u533a","timeData":["2021-06-30","2020-12-31","2020-06-30"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u534e\u5357\u897f\u5357\u5730\u533a","timeData":["2021-06-30","2020-12-31","2020-06-30"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u6536\u5165","timeData":["2021-06-30","2020-12-31"],"lineData":[0,100],"columnData":[0,100],"unit":["0.00","100.00\u4e07"]},{"name":"\u4e1c\u5317\u534e\u5317\u5730\u533a","timeData":["2021-06-30","2020-12-31","2020-06-30"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u5176\u4ed6","timeData":["2021-06-30","2020-12-31","2020-06-30"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]}]}}

营业收入 X

单位（%） 单位（万元）
注：通常在中报、年报时披露　
业务名称 营业收入(元) 收入比例 营业成本(元) 成本比例 利润比例 毛利率
按产品 抗蛇毒血清 5906.45万 61.58% 559.72万 36.80% 67.16% 90.52%
马破免疫球蛋白 3576.06万 37.28% 961.38万 63.20% 32.84% 73.12%
其他业务收入 109.43万 1.14% - - - -
抗狂犬病血清 200.00 0.0002% 300.00 0.0020% -0.0001% -50.00%
按地区 华东华中地区 6647.17万 69.30% - - - -
华南西南地区 2745.88万 28.63% - - - -
其他业务收入 109.43万 1.14% - - - -
东北华北地区 81.75万 0.85% - - - -
其他 7.73万 0.08% - - - -

董事会经营评述

　　（一）营业收入
　　1、营业收入构成
　　公司营业收入主要来自于主营业务，报告期各年度实现营业收入分别为11,988.13万元、14,433.09万元、18,809.71万元及7,559.94万元，最近三年复合增长率为25.26%，呈现较快的增长趋势。
　　2017年和2019年其他业务收入分别为提供“免疫马血浆与抗毒素样品的制备”、“抗毒素中试生产与检定研究服务”的技术服务收入，2020年1-6月其他业务收入为销售新冠病毒马免疫血浆收入。
　　2、按产品类别划分的主营业务收入
　　报告期内，公司主营业务收入主要来自于抗蛇毒血清和马破免疫球蛋白产品，其中抗蛇毒血清产品是营业收入增长的主要来... 查看全部▼

　　（一）营业收入
　　1、营业收入构成
　　公司营业收入主要来自于主营业务，报告期各年度实现营业收入分别为11,988.13万元、14,433.09万元、18,809.71万元及7,559.94万元，最近三年复合增长率为25.26%，呈现较快的增长趋势。
　　2017年和2019年其他业务收入分别为提供“免疫马血浆与抗毒素样品的制备”、“抗毒素中试生产与检定研究服务”的技术服务收入，2020年1-6月其他业务收入为销售新冠病毒马免疫血浆收入。
　　2、按产品类别划分的主营业务收入
　　报告期内，公司主营业务收入主要来自于抗蛇毒血清和马破免疫球蛋白产品，其中抗蛇毒血清产品是营业收入增长的主要来源。
　　目前，抗蛇毒血清为国内独家产品，世界卫生组织指出抗蛇毒血清是治疗蛇伤的唯一特效药，报告期内销售收入快速增长，自2017年的5,280.13万元增长到2019年的11,171.42万元，复合增长率为45.46%，2020年1-6月收入为4,575.32万元，抗蛇毒血清产品收入占主营业务收入比例从2017年的44.15%增长到2020年上半年的60.55%，是公司最重要的收入增长来源。
　　（1）抗蛇毒血清
　　报告期内，公司各类抗蛇毒血清产品的收入均逐年增长，其中：抗蝮蛇毒血清产品为公司抗蛇毒血清产品收入的首要构成，报告各期收入占比均在50%以上，受到其他抗蛇毒血清产品销售规模增长较快的影响，收入占比有所下降；公司抗眼镜蛇毒血清产品在报告期内呈现大幅上涨趋势，收入占比也逐年上升。报告期前期，公司少量生产并销售抗眼镜蛇毒血清产品以观察市场需求情况，由于抗眼镜蛇毒血清存在较大的市场需求，报告期内公司扩大了抗眼镜蛇毒血清产品生产并加强了推广力度，产品销售收入逐年增长。
　　抗银环蛇毒血清产品整体的销售规模相较于其他品种而言较小，由于其市场整体需求量较少、需求存在一定的不稳定性，各年度的收入存在波动。
　　抗五步蛇毒血清产品报告期内的销售收入占比较为稳定。
　　（2）马破免疫球蛋白
　　马破免疫球蛋白是破伤风抗毒素的升级产品，目前为国内独家生产，报告期各期的收入分别为6,675.31万元、6,419.67万元、7,609.99万元和2,979.63万元，占公司主营业务收入的比例为55.82%、44.48%、40.52%和39.43%。
　　（3）抗狂犬病血清
　　公司的抗狂犬病血清产品仍在不断进行技术升级研发，报告期内仅进行了少量试销售，尚未形成规模化收入。
　　3、按客户所在地区划分的主营业务收入
　　从销售地区来看，华东华中地区为公司的重要销售区域，2017年至2019年的收入分别为10,298.54万元、10,425.40万元以及12,656.44万元，销售额持续上升，该地区为蛇伤高发区，公司也在此区域耕耘多年，因此来自于此区域的销售收入占比高。华南西南地区蛇伤虽为高发区，但由于公司现有资源有限、投入相对较少，产品在此区域销售金额相应占比低，是未来的重点发展方向，该地区销售占比从2017年占比10.09%上升到2019年的30.11%。东北华北区域因蛇伤发生量相对其他区域较少，因此公司产品在此区域的销售金额占比最小。
　　4、按内销和外销类别划分的主营业务收入
　　公司主要的经销商集中在国内，国外占比较低。2017年、2018年、2019年以及2020年1-6月的国外收入比例分别为1.68%、0%、0.49%以及1.53%，外销主要为出口韩国的抗蝮蛇毒血清原液
　　5、销售数量、价格与结构变化对营业收入的影响
　　（1）各类抗蛇毒血清
　　公司的抗蛇毒血清是毒蛇咬伤临床抢救与治疗工作中不可或缺的药品。
　　2015年6月，发改价格〔2015〕904号文《关于印发推进药品价格改革意见的通知》全面落实执行，原本对于药品最高出厂价格和最高零售价格的管控逐步放开。在该文件发布前，公司各类抗蛇毒血清产品价格多年未发生变化，上述文件实行后，公司对抗蛇毒血清产品价格进行上调，2017至2018年度公司抗蛇毒血清产品的销售价格有较大幅度的上涨，收入随之增长。2018年12月《蛇伤共识》指引出台后，医疗机构有了更加科学规范的用药指导，促进了抗蛇毒血清产品2019年度销量的增长。
　　（2）马破免疫球蛋白
　　报告期内马破免疫球蛋白平均单价相对稳定，马破免疫球蛋白收入的变动主要是由马破免疫球蛋白销量略有波动所致。 收起▲

同花顺个股页面 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。